

Curriculum Vitae

Tzu-Tang Wei, Ph.D.

Education: Ph.D. in Pharmacology, National Taiwan University (2015)
M.S. in Pharmacology, National Cheng Kung University (2010)
B.S. in Pharmacy, Taipei Medical University (2008)

Current Position:

2023~ Associate Professor, Department of Pharmacology, National Taiwan University
2020~ Faculty Member, Taiwan International Graduate Program in Chemical Biology and Molecular Biophysics (TIGP-CBMB), Academia Sinica

Professional Experience:

2019-2023 Assistant Professor, Department of Pharmacology, National Taiwan University
2016-2019 Postdoctoral Fellow, Cardiovascular Institute, Stanford University, CA, USA

Major Awards and Honors (selected):

2024 FutureTech Award, National Science and Technology Council (NSTC), Taiwan
2024 NARLabs R&D Service Platform Achievement Award, National Applied Research Laboratories (NARLabs), Taiwan
2024 Distinguished Teaching Award, National Taiwan University
2024 Best Teaching Award, National Taiwan University Medical College Alumni Association
2024 Dr. Hong-Yen Hsu Academic Award of Chinese Medicine, Hsu Hung-Yuan Foundation
2023 Excellent Teaching Award, National Taiwan University
2023 College Student Research Creativity Award, National Science and Technology Council (NSTC), Taiwan (As advisor, Recipient: undergraduate student Pin-Jung Liu)
2022 New Investigator Travel Award, Basic Cardiovascular Sciences (BCVS) Scientific Conference, American Heart Association (AHA)
2022 Excellent Teaching Award, National Taiwan University
2019 Einstein Program (2019-2023), Ministry of Science and Technology (MoST), Taiwan
2019 North American Cannabis Summit Scholarship, Tobacco-Related Disease Research Program (TRDRP) of California, USA
2018 Venture Studio Program (2018-2019), Graduate School of Business, Stanford University
2017 Excellent Doctoral Thesis Award, National Taiwan University College of Medicine
2016 Postdoctoral Fellowship (2016-2019), Ministry of Science and Technology (MoST), Taiwan
2016 Excellent Poster Award, International Symposium on Advanced Biomedical Sciences, China Medical University, Taiwan
2015 Dr. Tsungming Tu Outstanding Thesis Award, The Pharmacological Society in Taiwan
2014 National Innovation Award, Institute of Biotechnology and Medicine Industry, Taiwan
2014 Outstanding Poster Award, 15th IUBMB-24th FAOBMB-TSBMB International Conference
2014 Stanford SPARK Program, International Biomedical-Innovation and Entrepreneurship Training Course, Australia (Mentor: Dr. Kevin Grimes/Stanford University & Dr. Michael Wallach/University of Technology Sydney)

Peer Reviewed Publications (selected):

- DJ Chung, CH Wang, PJ Liu, SK Ng, CK Luo, SH Jwo, CT Li, DY Hsu, CC Fan, **TT Wei**.
“Targeting CREB-binding protein (CBP) abrogates colorectal cancer stemness through epigenetic

regulation of C-MYC.” *Cancer Gene Ther.* 2024 Nov;31(11):1734-1748.

- SK Ng, DJ Chung, LC Chang, CK Luo, SH Jwo, YH Lee, JS Lin, CH Wang, **TT Wei**. “The protective effect of cannabinoids against colorectal cancer cachexia through modulation of inflammation and immune responses.” *Biomed Pharmacother.* 2023 May;161:114467.
- EC Brun, ZY Hong, YM Hsu, CT Wang, DJ Chung, SK Ng, YH Lee, **TT Wei**. “Stability and activity of interferon beta to treat idiopathic pulmonary fibrosis with different nebulizer technologies.” *J Aerosol Med Pulm Drug Deliv.* 2023 Apr;36(2):55-64.
- **TT Wei**, M Chandy, M Nishiga, A Zhang, KK Kumar, D Thomas, A Manhas, S Rhee, JM Justesen, IY Chen, HT Wo, S Khanamiri, JY Yang, FJ Seidl, NZ Burns, C Liu, N Sayed, JJ Shie, CF Yeh, KC Yang, E Lau, KL Lynch, M Rivas, BK Kobilka, JC Wu. “Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation.” *Cell.* 2022 May 12;185(10):1676-1693.e23.
- PH Chou, CK Luo, N Wali, WY Lin, SK Ng, CH Wang, M Zhao, SW Lin, PM Yang, PJ Liu, JJ Shie, **TT Wei**. “A chemical probe inhibitor targeting STAT1 restricts cancer stem cell traits and angiogenesis in colorectal cancer.” *J Biomed Sci.* 2022 Mar 22;29(1):20.
- CK Luo, PH Chou, SK Ng, WY Lin, **TT Wei**. “Cannabinoids orchestrate cross-talk between cancer cells and endothelial cells in colorectal cancer.” *Cancer Gene Ther.* 2022 May;29(5):597-611.
- CW Huang*, SY Lee*, **TT Wei***, YH Kuo, ST Wu, HC Ku. “A novel caffeic acid derivative prevents renal remodeling after ischemia/reperfusion injury.” *Biomed Pharmacother.* 2021 Oct;142:112028. (*Co-first author)
- **TT Wei**, YT Lin, SP Tang, CK Luo, CT Tsai, CT Shun, CC Chen. “Metabolic targeting of HIF-1 α potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer.” *Oncogene.* 2020 Jan;39(2):414-427
- **TT Wei**, YT Lin, YC Lin, CT Shun, JM Fang, CC Chen. “Prevention of Colitis and Colitis-associated Colorectal Cancer by a Novel Polypharmacological HDAC Inhibitor.” *Clin Cancer Res.* 2016 Aug 15;22(16):4158-69.
- **TT Wei**, YT Lin, YC Lin, CT Shun, YH Lin, JB Chen, NW Chen, JM Fang, MS Wu, LC Chang, KY Tai, JT Liang, CC Chen. “Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer.” *EBioMedicine.* 2016 Aug;10:124-36.

Patents:

- JH Lin, CC Chen, JM Fang, JB Chen, TR Chern, **TT Wei**. “3, 5, N-trihydroxy-alkanamide and derivatives: method for making same and use thereof”. US provisional patent (61/674,290); US patent (US 9,353,061 B2); PCT/US2013/051247; Invention Patents in Taiwan (I455912); China patent application (CN 201380038656.6). (Assignee: NTU and Academia Sinica) (Tech transfer to Taiwan J Pharmaceuticals).
- JH Lin, CC Chen, JM Fang, JB Chen, TR Chern, **TT Wei**. “Dual-action inhibitors against histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase.” US provisional patent (61/756,453); US patent (US 9,115,116 B2); Invention Patents in Taiwan (I537280). (Assignee: NTU and Academia Sinica) (Tech transfer to Taiwan J Pharmaceuticals).
- NW Su, C Hsu, DJ Chung, **TT Wei**. “Application of genistein and its phosphate ester derivative and pharmaceutical composition comprising the same.” Invention Patents in Taiwan (I845284); US patent (US 2024/0358672 A1). (Assignee: NTU) (Tech transfer to GeneFerm Biotechnology).